What is CJC-1295 ipamorelin? Learn how this two-peptide GH stack works, how the DAC form differs, reported effects, side effects, and FDA status in the US.
CJC-1295 and ipamorelin is a two-peptide stack used in research settings to stimulate growth hormone (GH) release. CJC-1295 is a long-acting growth hormone-releasing hormone (GHRH) analog, while ipamorelin is a selective ghrelin-receptor agonist that triggers GH pulses. The two are combined because they hit separate receptors — and neither peptide is FDA-approved for human use in the United States.
What Is CJC-1295 Ipamorelin?
CJC-1295 is a synthetic copy of growth hormone-releasing hormone, also called GRF(1-29) or modified GRF. The letters “CJC” are generally attributed to ConjuChem, the company that developed the compound, and 1295 is its internal identification number. Anyone typing what is cjc 1295 peptide into a search bar is really asking about a lab-made version of a signal the pituitary gland already responds to.
Ipamorelin is much smaller — a five-amino-acid peptide developed in the 1990s as a “selective” GH secretagogue. Early research suggested it raised GH with far less impact on cortisol, prolactin, and appetite than older compounds such as GHRP-6.
When a vendor sells a CJC-1295/ipamorelin blend, the vial usually contains CJC-1295 without DAC plus ipamorelin in a fixed ratio. Some suppliers offer the with-DAC version instead, and that difference changes the behavior of the stack considerably.
How the CJC-1295 and Ipamorelin Stack Works
The body releases GH in pulses, mostly during deep sleep and after intense exercise. Two receptor systems drive those pulses:
- GHRH receptors — activated by CJC-1295, which tells the pituitary to make and release GH.
- Ghrelin receptors (GHS-R) — activated by ipamorelin, which increases the size of each pulse.
Stacking the two is meant to produce a larger GH response than either peptide alone. That logic comes from older research pairing GHRH with secretagogues like GHRP-2 and GHRP-6, not from trials of ipamorelin specifically.
CJC-1295 With DAC vs Without DAC
The biggest variable in this stack is which form of CJC-1295 you are looking at. DAC stands for Drug Affinity Complex, a chemical tag that lets the peptide bind to albumin in the bloodstream and stay active for days instead of minutes.
| Feature | CJC-1295 with DAC | CJC-1295 without DAC | Ipamorelin |
|---|---|---|---|
| Other names | DAC:GRF, CJC-1295 DAC | Mod GRF 1-29, CJC-1295 no DAC | IPA |
| Receptor targeted | GHRH receptor | GHRH receptor | Ghrelin / GHS-R |
| Approximate half-life | About 6-8 days | About 30 minutes | About 2 hours |
| GH and IGF-1 pattern | Sustained elevation | Short, pulse-like | Short, pulse-like |
| Common role in a stack | Rarely paired with ipamorelin | Most common partner | Amplifies the pulse |
| FDA status | Not approved for human use | Not approved for human use | Not approved for human use |
The with-DAC version keeps GH and IGF-1 elevated for days after a single dose, which is why it is sometimes described as creating a continuous “GH bleed.” The no-DAC version clears quickly and mimics a natural pulse, which is why it is the form most often paired with ipamorelin.
What Does CJC-1295 and Ipamorelin Do? Reported Effects
In a small study of healthy adults, a single dose of CJC-1295 with DAC raised mean GH levels and increased IGF-1 for up to six days. That remains the strongest published human data for CJC-1295 itself, and ipamorelin has very little human research behind it.
Anecdotal reports from users focus on:
- Deeper sleep and easier recovery
- Gradual increases in lean muscle mass
- Modest fat loss, particularly around the waist
- Better skin, hair, and joint comfort
None of those claims has been confirmed in controlled trials of the combination. Most online discussion about what is cjc 1295 ipamorelin used for traces back to forums, vendor blogs, and personal logs, which is why the question “does cjc-1295 ipamorelin work” is still genuinely open.
Safety, Side Effects, and Legal Status
Both peptides are sold as research chemicals labeled “not for human consumption.” The direct answer to is cjc-1295 ipamorelin fda approved is no — no version of this stack has FDA approval for any indication.
Side effects reported by users include:
- Redness, swelling, or pain at the injection site
- Headache, flushing, or lightheadedness after dosing
- Water retention and tingling or numbness in the hands
- Joint aches, fatigue, and increased appetite
Because CJC-1295 with DAC keeps IGF-1 elevated for days, there is a theoretical concern about long-term tissue growth. Anyone considering these compounds should speak with a licensed healthcare provider first, and competitive athletes should know that GH secretagogues are banned by WADA.
How It Compares With Other Peptides
People researching this stack usually compare it against other peptides that influence growth hormone or fat metabolism. The differences are substantial.
| Peptide | Primary action | FDA status | Main research focus |
|---|---|---|---|
| CJC-1295 + ipamorelin | GHRH and ghrelin receptor | Not approved | GH and IGF-1 stimulation |
| Tesamorelin | GHRH analog | Approved for excess abdominal fat in some adults with HIV | Prescription fat reduction |
| AOD 9604 | Fragment of human growth hormone | Not approved | Fat metabolism, not GH release |
| IGF-1 LR3 | Direct IGF-1 analog | Not approved | Acts downstream of GH |
Side-by-side searches like cjc-1295 ipamorelin vs tesamorelin are common, but the comparison is uneven: tesamorelin is the only one of these with FDA approval, and only for a narrow patient population.
Timing, Storage, and Other Common Questions
Questions about the best time to take cjc 1295 ipamorelin almost always come back to sleep. Natural GH release peaks during the first deep-sleep cycle, so users typically dose before bed or after training on an empty stomach. No clinical trial has validated any specific timing for the blend.
Practical details that come up repeatedly in peptide communities:
- Reconstituted vials are usually refrigerated and used within a few weeks.
- Lyophilized powder should stay cool, dry, and out of direct light.
- Sterile technique is standard, but sterility does not make a research chemical safe or legal for human use.
The Bottom Line
CJC-1295 and ipamorelin are two separate GH-releasing peptides combined to stimulate the pituitary from two directions. CJC-1295 provides the GHRH signal, ipamorelin amplifies the pulse, and the DAC version of CJC-1295 stretches the effect from minutes to days.
Human evidence for the stack is thin, every version is unapproved for human use in the US, and the muscle, fat-loss, and anti-aging claims attached to it are largely anecdotal. Anyone dealing with a hormone-related concern should talk with a qualified healthcare professional rather than a vendor.
Frequently Asked Questions
Is CJC-1295 ipamorelin FDA approved?
No. Neither CJC-1295 nor ipamorelin has FDA approval for human use, and both are sold as research chemicals labeled “not for human consumption.” Any product marketed as a CJC-1295/ipamorelin blend for human injection is unapproved and unregulated, so quality and purity are not guaranteed.
What does CJC-1295 and ipamorelin do?
CJC-1295 stimulates growth hormone release through the GHRH receptor, and ipamorelin amplifies that release through the ghrelin receptor. Together they raise GH and IGF-1 levels in the body. Claims about muscle growth, fat loss, and anti-aging benefits come mostly from user reports rather than controlled clinical trials.
How long does CJC-1295 stay in your system?
The with-DAC form of CJC-1295 has a half-life of roughly six to eight days, while CJC-1295 without DAC clears in about 30 minutes. Ipamorelin has a half-life of about two hours. The long half-life of the DAC version is one reason it is rarely stacked with ipamorelin.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.